Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Kairos presents positive preclinical outcomes of anti-tumor therapies at AACR IO

Kairos Pharma (NYSE:KAPA) announced the presentation of positive preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research and Immuno-Oncology (ACCR IO)...

February 26, 2025

Developments

Alligator reports encouraging OS for mitazalimab in metastatic pancreatic cancer

Alligator Bioscience (STO:ATORX) has announced updated results from its Phase 2 OPTIMIZE-1 study evaluating mitazalimab in combination with chemotherapy as a first-line treatment for metastatic pancreatic cancer...

February 26, 2025

Developments

IP highlights Istesso’s Phase 2b study findings of leramistat in RA

IP Group (LSE:IPO) has reported that Instesso has provided its shareholders with the results of its 12-week randomized, double-blind, placebo controlled Phase 2b study of leramistat in patients with moderate-to-severe...

February 25, 2025

Developments

First patient dosed in Aim’s Phase 2 study of Ampligen and Imfinzi in pancreatic cancer

AIM ImmunoTech (NYSE American:AIM) announced that the first new patient has been dosed in the Phase 2 study of its Ampligen and Astra Zeneca’s anti-PD-L1 immune checkpoint inhibitor, Imfinzi, as a potential combination...

February 25, 2025

Developments

OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) has announced that full efficacy and safety data from the induction period of the randomized, double-blind, placebo-controlled, Phase 2 CoTikiS study of...

February 24, 2025

Developments

PepGen reveals positive initial Phase 1 study results of PGN-EDODM1 in DM1

PepGen (NASDAQ:PEPG) has announced initial positive data from the five and ten mg/kg dose cohorts in its ongoing FREEDOM-DM1 Phase 1 study investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). PeoGen reports that...

February 24, 2025

Developments

USPTO grants OS NOA covering manufacturing of OST-HER2

OS Therapies (NYSE-A:OSTX) has announced that it has received a notice of allowance from the US Patent & Trademark Office (USPTO) covering the manufacturing methods required for OST-HER2. According to OS, the USPTO...

February 20, 2025

Developments

Hemostemix Licences CytoImmune’s BioReactor Technologies

Hemostemix (TSXV:HEM; OTCQB:HMTXF) has announced that it has secured an arm’s length perpetual, royalty-free global license to CytoImmune’s BioReactor stem cell technologies. Subject to the TSXV Exchange acceptance...

February 20, 2025

Developments

FDA fast tracks BioRestorative’s BRTX-100 in cLDD

BioRestorative Therapies (NASDAQ:BRTX) has announced that the FDA has granted Fast Track designation to the BRTX-100 stem cell program for the treatment of chronic lumbar disc disease (cLDD). “We are thrilled that the...

February 20, 2025

Developments

MOBILion showcases new mass spectrometry approach at US HUPO conference

Closely held MOBILion Systems has announced its participation in the 21st annual US HUPO conference this month in Philadelphia. The company will showcase its new Parallel Accumulation with Mobility Aligned Fragmentation...

February 19, 2025

Developments

AHN launches Ekso Bionics’ transformational robotic exoskeleton technology

Non-profit Allegheny Health Network (AHN) has introduced the groundbreaking EksoNR, a wearable, full-body robotic exoskeleton that assists patients recovering from neurological injury or disease. The weight-bearing...

February 19, 2025

Developments

First New Mexico Hospital leverages Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V:Pink; OTC:PYNKF) announced that CHRISTIS St. Vincent is the first hospital in New Mexico to use its optical coherence technology (OCT), S-Series OCT, to visualize tissue margins...

February 19, 2025

Developments

Theratechnologies resumes U.S. supply of EGRIFTA SV for HIV

Theratechnologies (TSX:TH; NASDAQ:THTX) announced that the FDA has granted approval for the company to resume U.S. distribution of its tesamorelin injection, EGRIFTA SV, for patients with HIV. According to the company...

February 14, 2025

Developments

Medicus provides update on Phase 2 study of D-MNA in BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of...

February 14, 2025

Developments

Pliant assembles expert panel to review bexotegrast trial data in IPF

Pliant Therapeutics (NASDAQ:PLRX) announced that, following a recommendation by the Data Safety Monitoring Board (DSMB), it will convene an independent panel of experts in pulmonary diseases and biostatistics to review...

February 13, 2025

Developments

Top-tier journal publishes NKGen’s trial results on troculeucel in AD

NKGen Biotech (NASDAQ:NKGN) announced that results from its initial dose-escalation Phase 1 trial of troculeucel for the treatment of Alzheimer’s disease (AD) have been published in the international, peer-reviewed...

February 13, 2025

Developments

Top-tier journal describes unique properties of Aclaris’ ATI-2138

Aclaris Therapeutics (NASDAQ:ACRS) has announced that a publication in The Journal of Pharmacology and Experimental Therapeutics describes the unique properties its investigational drug, ATI-2138, which is in...

February 12, 2025

Developments

Windtree highlights abstract on istaroxime presented at 2025 THT conference

Windtree Therapeutics (NasdaqCM:WINT) has announced that an abstract discussing the positive results of SEISMiC, its Phase 2b study of istaroximine in cardiogenic shock, was presented by Dr. Matteo Pagnesi, a...

February 12, 2025

Developments

FOX 26 interview with Baylor’s Alastair Thompson discusses achieving clear margins in breast cancer surgery with Perimeter’s investigational B-Series OCT with ImgAssist AI 2.0

A FOX26 news interview featuring Dr. Alastair Thompson, a surgical oncologist at Baylor College of Medicine and the lead principal investigator of Perimeter Medical Imaging AI’s (TSX: PINK; OTC: PYNKF) pivotal trial on...

February 11, 2025

Developments

Firefly accepted into NVIDIA Connect program

Firefly Neuroscience (NASDAQ:AIFF) has announced its acceptance into the NVIDIA Connect program, granting access to advanced software development resources, frameworks, software development kits, and a global ecosystem...

February 11, 2025

Developments

Eledon’s tegoprubart plays key role in recent GM pig kidney transplant

Eledon Pharmaceuticals (NASDAQ:ELDN) has announced that its investigational anti-CD40L antibody, tegoprubart, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a...

February 11, 2025

Developments

OIO grants HEALWELL regulatory approval to acquire Orion Health

HEALWELL AI (TSX:AIDX; QTCQX:HWAIF) has announced that New Zealand’s Overseas Investment Office (OIO) has granted consent for the company to acquire all ordinary shares of Orion Health, based in Auckland, New Zealand...

February 10, 2025

Subscribe